<DOC>
	<DOC>NCT00752570</DOC>
	<brief_summary>This clinical trial will compare the efficacy and safety of the combination of AMG 386 and FOLFIRI with FOLFIRI alone in second line treatment of metastatic colorectal cancer.</brief_summary>
	<brief_title>A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Trebananib</mesh_term>
	<criteria>Histologically confirmed adenocarcinoma of the colon or rectum in patients who are presenting with metastatic disease One and only one prior chemotherapy regimen for metastatic disease consisting of the combination of a fluoropyrimidinebased chemotherapy and an oxaliplatinbased chemotherapy. Prior adjuvant chemotherapy used prior to the onset of metastatic disease is permitted At least one uni dimensionally measurable lesion per modified RECIST criteria. All sites of disease must be evaluated &lt;= 28 days before randomization Radiographically documented disease progression per modified RECIST criteria either while receiving or &lt;= 6 months after the last dose of prior chemotherapy regimen for metastatic disease ECOG performance status of 0 or 1 Man or woman &gt;= 18 years of age Adequate end organ assessments by laboratory studies (hematological and chemistries) Life expectancy &gt;= 3 months Exclude subjects with a history of prior malignancy, except: Malignancy treated with curative intent and with no known active disease present for &gt;= 3 years before enrollment and felt to be at low risk for recurrence by treating physician Adequately treated nonmelanomatous skin cancer or lentigo maligna without evidence of disease Adequately treated cervical carcinoma in situ without evidence of disease Prostatic intraepithelial neoplasia without evidence of prostate cancer Prior irinotecan therapy Systemic chemotherapy, hormonal therapy, or immunotherapy &lt;= 21 days prior to randomization Experimental or approved proteins/antibodies (eg, bevacizumab) &lt;= 30 days prior to randomization Clinically significant cardiac disease within 12 months prior to randomization, including myocardial infarction, unstable angina, grade 2 or greater peripheral vascular disease, cerebrovascular accident, transient ischemic attack, congestive heart failure, or arrhythmias not controlled by outpatient medication, percutaneous transluminal coronary angioplasty/stent Known allergy or hypersensitivity to irinotecan, 5 FU (known dihydropyrimidine dehydrogenase deficiency) or leucovorin Active inflammatory bowel disease or other bowel disease causing chronic diarrhea (defined as &gt;= CTC grade 2 [CTCAE version 3.0])</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Metastatic Colorectal Cancer</keyword>
	<keyword>colorectal cancer</keyword>
	<keyword>colon cancer</keyword>
</DOC>